Drug discovery

In Silico Structure-based Drug Design – Shifting the bottleneck? By Dr Jonathan Heal Drug Discovery The use of in silico methods in drug design has grown significantly in popularity over the past couple of years. Indeed many pharma companies have already adopted some type of virtual screening capability to complement HTS methods. Will we eventually […]

Surface Plasmon Resonance’s impact on drug discovery – resolution, throughput and versatility By Dr David G. Myszka and Dr Rebecca L. Rich Surface plasmon resonance (SPR) biosensors have rapidly become a standard tool within the pharmaceutical and biotechnology industries. Label-free, real-time measurements are the calling card for this technology, which can be used to monitor […]

The role of ZEBRAFISH in drug discovery By Dr Paul Goldsmith and Roberto Solari The NIH has ranked the Zebrafish as the third most important experimental organism after man, the Sanger Centre is sequencing the genome and many medical researchers are shifting over to it. But will the zebrafish have a role in drug discovery? […]

TRANSCRIPTOMICS – Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or the discovery of drugs that […]

A business model for sustainable, strategic relationships By Dr Douglas J. Squires and Dr James E. McClurg Historically relationships between CROs and pharmaceutical and biotech companies, and the results of these relationships, have not met shared expectations for strategic value exchange. This article presents a business model for achieving a sustainable relationship that is attractive […]

By Dr Lynn Butler The barriers to establishing an equitable partnership between biotechs and big pharma are high and many partnerships, once established, do not deliver the tangible and non-tangible value expected by the licensor. This article addresses how to develop and implement a partnering strategy that will deliver attractive value, avoid the erosion of […]

The transition from scientist to business manager in a biotech/drug discovery start-up By Dr Paul Charlton The move from a successful scientific career into senior management of a high technology start-up company frequently presents a paradigm shift for the individual in the way that they must manage both themselves and their team. This article aims […]

Compound Management comes of age By Ian Yates The changing role of compound management in recent years has seen an often under-valued and under-resourced function being recognised as a key part of the drug discovery process. This article examines the challenges faced by compound management teams and, at a high level, some of the solutions […]

Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Does access to more targets mean a higher probability […]

Second-Generation Protein Drugs By Dr Jeffrey C.Way The first biotech revolution was catalysed in the late 1970s with the development of recombinant DNA technology. This revolution generated numerous billion-dollar protein drugs such as erythropoietin and the interferons. Now that the patents on these drugs are expiring, will second generation proteins, the children of the biotech […]